London, 23 March, 2020 – Freeline, a biotechnology company focused on developing curative gene therapies for chronic systemic diseases, today announced the appointemnt of Julie Krop M.D., as Chief Medical Officer (CMO) effective 1 April, 2020.
"Julie brings to Freeline broad and deep experience in guiding clinical stage therapies for rare and complex disorders to registration," said Chris Hollowood, Chairman of Freeline Therapeutics. "Given her extensive and successful track record in clinical drug development at leading biotech and pharmaceutical companies, she will be a tremendous asset to us as we build Freeline into a leading global systemic gene therapy company. Julie will be based in Boston, Massachusetts, where she will lead Freeline’s global clinical and medical activities and direct the expansion of Freeline’s clinical activities in the US.”
Dr Krop most recently served as the CMO of AMAG Pharmaceuticals, where she oversaw the clinical, medical affairs, program management, pharmacovigilance, and regulatory functions. During her tenure she built a fully integrated development organization and was responsible for overseeing three successful regulatory approvals. Dr Krop has more than 20 years of drug development experience across multiple therapeutic areas, including rare and orphan indications. Prior to joining AMAG, she held leadership positions at Vertex, Pfizer, Millennium, and Stryker Regenerative Medicine. Dr Krop received her undergraduate and medical degrees from Brown University. She is board certified in Internal Medicine and completed a Robert Wood Johnson Foundation Clinical Scholar Fellowship as well as an Endocrinology fellowship at the Johns Hopkins University School of Medicine. Dr Krop is also active in the Boston Chief Medical Officer community. She serves on the steering committee for the Boston CMO Network and has Co-Chaired the Annual CMO 360 Summit for the past three years.
"Freeline’s next generation AAV capsid gene therapy platform represents an innovative advancement for the treatment of patients with genetic disorders,” said Julie Krop. “It is an exciting time to join the Company with its hemophilia B and Fabry programs in the clinic and Gaucher and hemophilia A right behind. I look forward to working with the talented Freeline team to progress its gene therapy pipeline through the regulatory process towards registration.”